Cisplatin Plus Gemcitabine for Treatment of Breast Cancer Patients with Brain Metastases: a Preferential Option for Triple Negative Patients?

医学 吉西他滨 养生 中性粒细胞减少症 内科学 耐受性 白细胞减少症 乳腺癌 三阴性乳腺癌 肿瘤科 化疗 胃肠病学 转移性乳腺癌 顺铂 人口 外科 癌症 不利影响 环境卫生
作者
Çiğdem Erten,Lütfiye Demir,İşıl Somali,Ahmet Alacacıoğlu,Yüksel Küçükzeybek,Murat Akyol,Alper Can,Ahmet Dirican,Vedat Bayoğlu,Mustafa Oktay Tarhan
出处
期刊:Asian Pacific Journal of Cancer Prevention [Asian Pacific Organization for Cancer Prevention]
卷期号:14 (6): 3711-3717 被引量:22
标识
DOI:10.7314/apjcp.2013.14.6.3711
摘要

Background: To assess the efficacy and tolerability of Cisplatin plus Gemcitabine combination in patients with brain metastases (BM) from breast cancer (BC). Materials and Methods: Eighteen BC patients with BM who were treated with Cisplatin plus Gemcitabine regimen between 2003-2011 were evaluated. Results: A median of 6 cycles of this regimen were received, in fifteen patients (83.3%) as first-line chemotherapy, in 2 as second-line and in 1 as third-line after diagnosis of BM. Dose reduction was performed in 11 (61.1%) patients; major reasons were neutropenia and leukopenia. Grade III neutropenia and Grade II trombocytopenia rates were 33.3% and 16.7% respectively. Overall response rate (ORR; complete+partial response rate) was 33.4% (n=6) for the entire study population; triple negative patients achieved an 66.6% ORR while hormone receptor (HR) positive patients had 25% and HER2 positive patients 12.5%. Median progression-free survival was 5.6 months (2.4-8.8 months, 95%CI) and longer in patients with triple negative breast cancer (TNBC) (median 7.4 months, 95%CI, 2.4-12.3 months) than the patients with other subtypes (median 5 months for HER2 positive and 3.6 months for HR positive patients). Median PFS of the patients with TNBC who received this regimen as first-line was 9.2 months (5.2-13.2 months, 95%CI). Conclusions: Cisplatin plus Gemcitabine may be a treatment option for patients with BM from breast cancer. Longer PFS and higher response rates are results that support the usage of this regimen especially for the triple negative subtype. However, further prospective and randomized trials are clearly required to provide more exact information.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Ava应助不懂采纳,获得10
刚刚
1秒前
SUKAZH完成签到,获得积分10
1秒前
2秒前
2秒前
优美水彤完成签到,获得积分10
2秒前
3秒前
3秒前
5秒前
清浅发布了新的文献求助10
6秒前
小成发布了新的文献求助10
6秒前
6秒前
lan发布了新的文献求助10
7秒前
年华发布了新的文献求助10
7秒前
小二郎应助淡然的冬寒采纳,获得10
9秒前
9秒前
zjl发布了新的文献求助10
10秒前
A1234567发布了新的文献求助10
11秒前
通天塔发布了新的文献求助10
12秒前
12秒前
饱满书文发布了新的文献求助20
12秒前
不懂发布了新的文献求助10
13秒前
最牛的kangkang关注了科研通微信公众号
13秒前
郝优佳完成签到,获得积分10
15秒前
Hawk发布了新的文献求助10
16秒前
打打应助CC采纳,获得10
17秒前
小成完成签到,获得积分10
19秒前
20秒前
颜瑞完成签到 ,获得积分10
20秒前
21秒前
甜言蜜语完成签到,获得积分10
24秒前
king19861119完成签到,获得积分0
25秒前
25秒前
贺雪完成签到,获得积分10
26秒前
Yallabo完成签到,获得积分10
27秒前
Viviane完成签到,获得积分10
27秒前
ri_290发布了新的文献求助10
28秒前
grs完成签到,获得积分10
29秒前
29秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3136456
求助须知:如何正确求助?哪些是违规求助? 2787471
关于积分的说明 7781435
捐赠科研通 2443406
什么是DOI,文献DOI怎么找? 1299154
科研通“疑难数据库(出版商)”最低求助积分说明 625359
版权声明 600939